In Brief: UroMed
This article was originally published in The Gray Sheet
UroMed: Corporate restructuring is anticipated to include a reduction of 32 employees from the firm's 188-person work force, the firm states in a June 2 release. The cuts are part of an effort to reduce operating costs at the company, which has suffered from "significantly slower" than anticipated market acceptance of its Reliance urinary control insert for female urinary stress incontinence following FDA approval in August 1996 ("The Gray Sheet" Aug. 26, 1996, p. 3). John Simon, chairman and CEO, notes the firm expects to update investors on "a number of significant product activities before the end of the calendar year"...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.